Long-term outcomes of an advanced hybrid closed-loop system: A focus on different subpopulations

• Published in: Diabetes research and clinical practice Vol. 191; p. 110052
• Main Authors: Beato-Víbora, Pilar Isabel, Ambrojo-López, Ana, Fernández-Bueso, Mercedes, Gil-Poch, Estela, Javier Arroyo-Díez, Francisco
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.09.2022
• Subjects: Artificial pancreas; Closed-loop systems; Hypoglycaemia; Type 1 diabetes; Artificial pancreas; Closed-loop systems; Type 1 diabetes; Hypoglycaemia
• ISSN: 0168-8227; 1872-8227; 1872-8227
• DOI: 10.1016/j.diabres.2022.110052

The long-term benefit provided by advanced hybrid closed-loop (AHCL) systems needs to be assessed in general populations and specific subpopulations. A prospective evaluation of subjects initiating the AHCL system 780G was performed. Time in range (70–180 mg/dl) (TIR), <70 mg/dl, <54 mg/dl, >180 mg/dl and >250 mg/dl were compared, at baseline and after one year, in different subpopulations, according to previous treatment (pump vs MDI), age (> or ≤25 years old) and hypoglycaemia risk at baseline. 135 subjects were included (age: 35 ± 15 years, 64 % females, diabetes duration: 21 ± 12 years). An increase in TIR was found, from 67.26 ± 11.80 % at baseline to 77.41 ± 8.85 % after one year (p < 0.001). All the subgroups showed a significant improvement in TIR, time > 180 mg/dl and >250 mg/dl. At the 1-year evaluation, no significant differences were found, between previous pump users and MDI subjects. Children and young adults had a lower time < 70 mg/dl than adults. Subjects with a high risk of hypoglycaemia at baseline had a higher time spent at <70 mg/dl and <54 mg/dl than low-risk individuals. The initial benefit provided by the AHCL system is sustained in the long term. MDI subjects obtain the same outcomes as subjects with pump experience.